Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET

Company Participants

Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications

Yvonne Greenstreet - Chief Executive Officer

Tolga Tanguler - Chief Commercial Officer

Pushkal Garg - Chief Medical Officer

Jeff Poulton - Chief Financial Officer

Conference Call Participants

Ritu Baral - Cowen

David Lebowitz - Citi

Tazeen Ahmad - Bank of America Securities

Maury Raycroft - Jefferies

Paul Matteis - Stifel

Gena Wang - Barclays

Luca Issi - RBC

Myles Minter - William Blair

Eliana Merle - UBS

Operator

Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder today's conference call is being recorded.

I would now like to turn the conference over to the company. Please go ahead.

Christine Lindenboom

Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During today’s call, as outlined on Slide 2, Yvonne will provide introductory remarks and general context. Tolga will provide an update on our global commercial progress. Pushkal will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions.

I’d like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as the date of this reporting and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements.

With that, I’d like to turn the call over to Yvonne. Yvonne?